{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Respiratory+Syncytial+Virus+Infections&page=3",
    "query": {
      "condition": "Respiratory Syncytial Virus Infections",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 264,
    "total_pages": 27,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Respiratory+Syncytial+Virus+Infections&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Respiratory+Syncytial+Virus+Infections&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T22:13:25.503Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05045144",
      "title": "A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "RSVPreF3(120 μg)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Flu Quadrivalent influenza vaccine (15 μg HA)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 49 Years · Female only"
      },
      "enrollment_count": 1586,
      "start_date": "2021-10-26",
      "completion_date": "2022-06-06",
      "has_results": true,
      "last_update_posted_date": "2023-10-05",
      "last_synced_at": "2026-11-19T22:13:25.503Z",
      "location_count": 5,
      "location_summary": "West Palm Beach, Florida • Stockbridge, Georgia • Peoria, Illinois + 2 more",
      "locations": [
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Stockbridge",
          "state": "Georgia"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Springfield",
          "state": "Missouri"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05045144"
    },
    {
      "nct_id": "NCT07734649",
      "title": "Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Immunization",
        "Human Metapneumovirus Immunization",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "RSV+HMPV vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Control Vaccine 3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Control Vaccine 4",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Control Vaccine 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Control Vaccine 1",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 2400,
      "start_date": "2026-07-22",
      "completion_date": "2028-05-03",
      "has_results": false,
      "last_update_posted_date": "2026-10-14",
      "last_synced_at": "2026-11-19T22:13:25.503Z",
      "location_count": 50,
      "location_summary": "Gadsden, Alabama • Vestavia Hills, Alabama • Huntington Beach, California + 43 more",
      "locations": [
        {
          "city": "Gadsden",
          "state": "Alabama"
        },
        {
          "city": "Vestavia Hills",
          "state": "Alabama"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07734649"
    },
    {
      "nct_id": "NCT06097299",
      "title": "A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Syncytial Virus"
      ],
      "interventions": [
        {
          "name": "mRNA-1345",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 349,
      "start_date": "2023-10-24",
      "completion_date": "2025-06-27",
      "has_results": true,
      "last_update_posted_date": "2026-08-18",
      "last_synced_at": "2026-11-19T22:13:25.503Z",
      "location_count": 47,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Banning, California + 41 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Banning",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06097299"
    },
    {
      "nct_id": "NCT02890381",
      "title": "Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of Age",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "RSV LID cp ΔM2-2 Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "24 Months",
        "sex": "ALL",
        "summary": "6 Months to 24 Months"
      },
      "enrollment_count": 17,
      "start_date": "2016-10-05",
      "completion_date": "2017-04-24",
      "has_results": true,
      "last_update_posted_date": "2021-11-05",
      "last_synced_at": "2026-11-19T22:13:25.503Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02890381"
    },
    {
      "nct_id": "NCT06397768",
      "title": "Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "RSV Immunization"
      ],
      "interventions": [
        {
          "name": "RSVt vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hepatitis B vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Streptococcus pneumoniae vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rotavirus vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Measles, mumps, and rubella vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Varicella virus vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "12 Months",
        "sex": "ALL",
        "summary": "6 Months to 12 Months"
      },
      "enrollment_count": 2226,
      "start_date": "2024-05-13",
      "completion_date": "2025-09-18",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-11-19T22:13:25.503Z",
      "location_count": 66,
      "location_summary": "Birmingham, Alabama • Grand Bay, Alabama • Mobile, Alabama + 55 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Grand Bay",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Bell Gardens",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06397768"
    },
    {
      "nct_id": "NCT04484935",
      "title": "Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "RSV Infection"
      ],
      "interventions": [
        {
          "name": "Nirsevimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "2 Years",
        "sex": "ALL",
        "summary": "0 Years to 2 Years"
      },
      "enrollment_count": 100,
      "start_date": "2020-08-19",
      "completion_date": "2023-02-17",
      "has_results": true,
      "last_update_posted_date": "2023-11-15",
      "last_synced_at": "2026-11-19T22:13:25.503Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Tampa, Florida • Syracuse, New York + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Syracuse",
          "state": "New York"
        },
        {
          "city": "North Charleston",
          "state": "South Carolina"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04484935"
    },
    {
      "nct_id": "NCT00435227",
      "title": "A Study to Evaluate a Single Intramuscular Dose of Motavizumab to Treat Children With Respiratory Syncytial Virus (RSV) Illness",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Participants Less Than 12 Months of Age With RSV Illness"
      ],
      "interventions": [
        {
          "name": "Motavizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Months",
        "maximum_age": "12 Months",
        "sex": "ALL",
        "summary": "0 Months to 12 Months"
      },
      "enrollment_count": 12,
      "start_date": "2007-03-20",
      "completion_date": "2008-05-31",
      "has_results": true,
      "last_update_posted_date": "2021-08-17",
      "last_synced_at": "2026-11-19T22:13:25.503Z",
      "location_count": 31,
      "location_summary": "Tucson, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 24 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00435227"
    },
    {
      "nct_id": "NCT02593071",
      "title": "Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vaccine or Placebo in the Prior Year.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Syncytial Virus (RSV)"
      ],
      "interventions": [
        {
          "name": "RSV-F Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Phosphate Buffer Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novavax",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 1330,
      "start_date": "2015-10",
      "completion_date": "2016-11",
      "has_results": false,
      "last_update_posted_date": "2022-05-27",
      "last_synced_at": "2026-11-19T22:13:25.503Z",
      "location_count": 10,
      "location_summary": "Redding, California • Stockbridge, Georgia • Lenexa, Kansas + 7 more",
      "locations": [
        {
          "city": "Redding",
          "state": "California"
        },
        {
          "city": "Stockbridge",
          "state": "Georgia"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02593071"
    },
    {
      "nct_id": "NCT01556607",
      "title": "A Trial to Assess the Safety, Tolerability and Pharmacokinetics of MDT-637 in Subjects With Intermittent, or Mild-to-Moderate Persistent, Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Drug Safety"
      ],
      "interventions": [
        {
          "name": "MDT-637",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MicroDose Therapeutx, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 10,
      "start_date": "2012-03",
      "completion_date": "2012-05",
      "has_results": false,
      "last_update_posted_date": "2012-05-22",
      "last_synced_at": "2026-11-19T22:13:25.503Z",
      "location_count": 1,
      "location_summary": "Costa Mesa, California",
      "locations": [
        {
          "city": "Costa Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01556607"
    },
    {
      "nct_id": "NCT06813872",
      "title": "Effectiveness of ABRYSVO® Maternal Respiratory Syncytial Virus (RSV) Vaccine Against RSV in Infants in Western Pennsylvania",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Respiratory Syncytial Viruses"
      ],
      "interventions": [
        {
          "name": "ABRYSVO Vaccination",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Months",
        "maximum_age": "6 Months",
        "sex": "ALL",
        "summary": "0 Months to 6 Months"
      },
      "enrollment_count": 1,
      "start_date": "2025-02-24",
      "completion_date": "2027-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-03",
      "last_synced_at": "2026-11-19T22:13:25.503Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06813872"
    }
  ]
}